ZM 306416 NEW
| Price | $40 | $64 | $139 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: ZM 306416 | CAS No.: 690206-97-4 |
| Purity: ≥95% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | ZM 306416 |
| Description | ZM 306416 (CB 676475), a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM). |
| In vivo | When acting on human thyroid follicular cells, ZM306416 (1 μM) decreased nuclear distribution and increased follicle formation; a significant increase in cell death was observed at 3 μM.ZM306416 weakly inhibited VEGF secretion and increased PlGF production.ZM306416 (<10 μM) had a significant inhibitory effect on steady-state phosphorylation of p42/44 MAPK but had no effect on the non phosphorylated forms, but had no effect on the expression of non-phosphorylated forms. In human thyroid follicular cells, ZM306416 (300 nM) completely inhibited PAA secretion, stimulated [125I] uptake, and silenced pVEGFR2 (Y1214) expression. ZM-306416 exhibited selective antiproliferative effects (IC50: 0.09 μM and 0.072 μM) when acting on the epidermal growth factor receptor-na?ve non-small cell (type) lung cancer cell lines H3255 and HCC4011. When acting on GeneBLAzer T-Rex RORγ-UAS-bla HEK293T cell line, ZM-306416 had a significant inhibitory effect on ERRα assay (IC50: 7.3 μM).ZM-306416 inhibited granule formation (IC50: 0.67 μM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 62 mg/mL (185.8 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | ZM-306416 | VEGFR | Inhibitor | ZM 306416 | CB-676475 | CB676475 | inhibit | ZM306416 | Vascular endothelial growth factor receptor |
| Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Sorafenib | Ibrutinib | Dasatinib | Regorafenib | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Cytoskeletal Signaling Pathway Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY